Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 1
1(33.3%)
3Total
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04661956Not ApplicableUnknown

The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in The Pulmonary Periphral Nodule

Role: lead

NCT04675463Not ApplicableUnknown

The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD

Role: lead

NCT04201990Phase 1Unknown

Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer

Role: lead

All 3 trials loaded